A new study from team OPTIMISTICC, published in @cellpress.bsky.social, shows that tumour-resident microbes are largely confined to cancers of the orodigestive tract. Together with team PROSPECT, they have generated a new resource and analytic pipeline. 👇 cancergrandchallenges.org/news/are-mic...

If you missed our Special Session at the #AACR Annual Meeting, you can still catch the key insights in the latest edition of Discover 👇 Take a closer look at the science with Allan Balmain and Mike Stratton: features.cancergrandchallenges.org/impact/

Such an honour to be included in this incredible special issue! We discuss how to support global team science and catalyse transformative discovery, drawing on our experience from @cancergrand.bsky.social "Just imagine what could be achieved in a system designed for true collaboration."

Tumours cannot be understood or treated in isolation, but interplay with the unique biology of their host— join us at this unique @cancergrand.bsky.social conference to discuss and debate cancer as a systemic disease! We have an amazing speaker line up from across the cancer research spectrum 👇

Next week is the final week to submit abstracts for Cancer and the Host: www.cancergrandchallenges.org/conferences/... 📥 Abstract deadline: 20 March 🗓️ 17–19 June 2026 📍The Royal Society, London This conference brings together leading researchers to explore cancer as a systemic disease. Read more 👇

The new @cancergrand.bsky.social teams have been announced! Read about the teams tackling cancer avoidance, mechanisms driving mutational signatures, the dark proteome, cancer neuroscience, & rewiring cancer cells now in Cancer Discovery @aacrjournals.bsky.social: aacrjournals.org/cancerdiscov...

An update to the Hallmarks of Cancer framework for understanding (and researching) what causes human cancers. spkl.io/63321Aqwbc Douglas Hanahan @cp-cell.bsky.social

The October issue of Cancer Discovery @aacrjournals.bsky.social is now online! The cover features two papers on the role of #ecDNA heterogeneity in tumor evolution and adaptation to therapy - you can find these papers and much more here: aacrjournals.org/cancerdiscov...

Move over AlphaFold3. Boltz-2 has arrived, bringing affinity prediction for protein-small molecule interactions! Can’t wait to see what this group does next. Congrats to all @gcorso.bsky.social Was a pleasure writing this: www.cancergrandchallenges.org/news/boltz-2...

Excited to unveil Boltz-2, our new model capable not only of predicting structures but also binding affinities! Boltz-2 is the first AI model to approach the performance of FEP simulations while being more than 1000x faster! All open-sourced under MIT license! A thread… 🤗🚀

Come and join us! We’re hiring a new Group Leader in Generative Biology at the @sangerinstitute.bsky.social Building AI models or the data to train them? Core funding of >$130M a year for a faculty of ~30. www.nature.com/naturecareer... acrobat.adobe.com/id/urn:aaid:... pls RT!

Mariam is part of team CANCAN, who are tackling the @cancergrand.bsky.social cachexia challenge!

We're hiring! The Journal of Cell Biology (JCB) seeks Scientific Editor or Senior Scientific Editor, dependent on experience. Join our team in New York City! More info 👉 careers.rockefeller.edu/jobs?keyword... #STEMjobs #LifeScienceJobs #PublishingJobs #ScienceJobs

Hello, we are AITHYRA! I am very excited to share with you the corporate identity of AITHYRA, the Research Institute for Biomedical AI. Check out the brand design video (sound on!) to learn more. **REMINDER** One week left to apply for Starting PI positions (Life Science and AI/ML). Come join us!

The 24/25 edition of @cancergrand.bsky.social progress magazine is now live! Including: 👉key advances from our funded teams 👉 the biggest themes in cancer research from early-onset cancers to AI and cancer as a systemic disease 👉our 7 new challenges features.cancerresearchuk.org/cancergrandc...